RECEIVED CENTRAL FAX CENTER

JAN 0 9 2004

OFFICIAL

FACSIMILE COVER SHEET

SALIWANCHIK, LLOYD & SALIWANCHIK
A Professional Association
2421 N.W. 41st Street
Suite A-1
Gainesville, FL 32606

Telephone (352) 375-8100 Facsimile (352) 372-5800

The information contained in this facsimile message is intended only for the personal and confidential use of the designated recipients named below. This message may be an attorney-client communication, and as such is privileged and confidential. If the reader of this message is not the intended recipient or an agent responsible for delivering it to the intended recipient, you are hereby notified that you have received this document in error, and that any review, dissemination, distribution, or copying of this message is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone and return the original message by mail. Thank you.

COMPANY:

U. S. Patent Office

FAX NO.:

(703) 872-9306

FROM:

Jeff Lloyd

DATE:

January 9, 2004

NUMBER OF PAGES (INCLUDING COVER SHEET): 7

MESSAGE:

Re:

U.S. Patent Application Serial No. 10/609,207

METHODS AND MATERIALS FOR TRANSFORMATION

Our Docket No.: WARF-100XCD1

Attached hereto:

- 1. Information Disclosure Statement (2 pages)
- 2. Form PTO/SB/08B (4 pages)

If you do not receive all pages or if any transmission is not legible, call the sender at (352) 375-8100.x

I hereby certify that this paper is being facsimile transmitted to the Patent and

Trademark Office on & Jaway 20

INFORMATION DISCLOSURE STATEMENT Patent Application Docket No. WARF-100XCD1 Serial No. 10/609,207

RECEIVED CENTRAL FAX CENTER

JAN 0 9 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner

(not yet assigned)

Art Unit

1638

Applicant(s)

Lada Rasachova

Scrial No.

10/609,207

Filed

w == 400

For

June 26, 2003

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §\$1.97 AND 1.98

Improved Materials and Methods for Transformation

Sir:

In accordance with 37 CFR §1.97 and §1.98(d), Applicants would like to bring to the attention of the Examiner the references cited in the following patent application:

U.S. Scrial No. 09/316,622; filed May 21, 1999

The subject application, Serial No. 10/609,207, claims the benefit under 35 USC §120 of the filing date of the above U.S. Patent Application Serial No.09/316,622. Applicants respectfully request that the copies of references cited during prosecution thereof be made of record in the 10/609,207 application. As copies of the references filed in the parent application and cited on the attached form PTO-1449 will be found in the parent casefile, copies of those references are not provided herewith.

2

Docket No. WARF-100XCD1 Serial No. 10/609,207

It is respectfully requested that the references cited in the above-noted parent application be considered in the examination of the subject application and their consideration be made of record.

Applicants respectfully assert that the substantive provisions of 37 CFR §\$1.97 and 1.98 are met by the foregoing statements.

Respectfully submitted,

Jeff Llo

Registration No. 35,589

Phone No.:

352-375-8100 352-372**-**5800

Fax No.: Address :

2421 N.W. 41st Street, Suite A-1

Gainesville, FL 32606-6669

JI./srp

Enclosure: PTO/SB/08A

PTO/SB/08A (10-01)
Approved for uso through 10/31/2002. OM0 06/1-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a void OMB control number.

Subs	Substitute for form 1449A/PTO				Complete if Known		
				. –	Application Number	10/609,207	
	INFORMATION DISCLOSURE				Filing Date	June 26, 2003	
31	STATEMENT BY APPLICANT (use as many shoots as necessary)			1 4	First Named Inventor	Lada Rasochova	
				sary)	Art Unit	1638	
					Examiner Name	(not yet assigned)	
SI	heel	1	of	4	Attorney Docket Number	WARF-100XCD1	

			U.S. PATENT DO	CUMENTS	
Examiner Initials*	Čilo No. 1	Document Numbar Numbor - Kind Cade ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Decument	Pagos, Columns, Linos, Whoro Relevant Passagos or Relevant Figures Appear
	Ü1	US- 5,853,716	12-29-1998	TATTERSALL et al.	
	U2	US- 5500360	03-19-1996	AHLQUIST et al.	
	UЗ	US- 5418153	05-23-1995	MORI et al.	
	U4	US- 582485G	10-20-1998	MORI et al.	
	Ülis	US- 5,851.757	12-22-1998	QLIVO el al.	
	UG	US- 5,817,512	10-00-1998	MORROW et al.	
	Ü/	ÚS-			
	Uß	US-			
	Ų9	U\$-			
	U10	US-	1		
	U11	US-			
	U12	US-			
	U13	US-			
	U14	US-	**************************************		
	U15	U3-			
	U16	US-			
	Ų17	US-			
	U18	US.			
Market (1777	U19	US			THE COMMENTS OF THE COMMENTS O
	Ų20	T US-			

		FOREIGN	PATENT DOCL	JMENTS		
Examiner Initials*	Cito No. 1	Foreign Palent Document Country Code * - Number* - Kind Code* (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Occument	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	14
	F1 F2					
	F3					
	F4 F5					
	ľ6					
	F7 Fa					
	F9		, , , , , , , , , , , , , , , , , , , ,			
	F10					

Examiner	Date
Cinnatura	
(Signature	Considered

^{*}EXAMINER: Initial it reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional), ² See Kind Codes of USPTO Patent Documents at www.ns.nin.gov or MPEP 901.04. ³ Enter Office that issued the document, by the bwo-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the sorial number of the potent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 10 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on this amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08U (10-01)

PTO/SS/08U (10-01)

Approved for use through 10/31/2002. OMB 0051-0031

U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449B/PTO **Application Number** 10/609,207 INFORMATION DISCLOSURE Filing Date June 26, 2003 STATEMENT BY APPLICANT First Named Inventor Lada Rasochova 1638 Group Art Unit (use as many shoots as necessary) **Examiner Name** (not yet assigned) WARF-100XCD1 Shoot 2 4 **Attorney Docket Number**

NON PATENT LITERATURE DOCUMENTS				
Examinor Initials*	Cita No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т2	
	R1	VERCHOT et al., J. of Virology (1995), 69(6): 3668-3674		
	R2	ALLISON et et., J. of Virology (1988), 62(10): 3581-3588		
	R3	FONTES et al., The Plant Cell (1994), 6: 405-416		
	174	BERGLUND et al., "Enhancing immune responses using suicidal DNA vaccines", Nature Biotech. (1998), 16: 562-565		
	R5	DE JONG and AHLQUIST, "A hybrid plant RNA virus made by transferring the noncapsid movement protein from a rod-shaped to an icosahedral virus is competent for systemic infection", <i>Proc. Natl. Acad. USA</i> (1992), 89: 6808-6812		
	RG	DINANT et al., "Bromovirus RNA replication and transcription requires compatibility between the polymerase- and helicase-like viral RNA synthesis proteins", J. Virol. (1993), 67: 7181-7189		
	R7	DZIANOTT and BUJARSKI, "Derivation of an infectious viral RNA by autolytic cleavage of in vitro transcribed viral cDNAs", Proc. Natl. Acad. Sci. USA (1989), 86: 4823-4827		
	R8	EDWARDS, "Mapping of the seed transmission determinants of barley stripe mosaic virus", MPMI (1995), 8: 906- 915		
77 777 187 187 187 187	R9	FRENCH and AHLQUIST, "Characterization and engineering of sequences controlling in vivo synthesis of brome mosaic virus RNA3", J. Virol. (1988), 62(7): 2411-2421		
	R10	HEMENWAY <i>et al.</i> , "Characterization of infectious transcripts from a potato virus X cDNA clone", <i>Virology</i> (1990), 175; 365-371		
	R11	ISHIKAWA et al., "In Vivo DNA expression of functional brome mesaic virus RNA Replicons in Saccharomyces cerevisioo", J. of Virology (1997), 71(10): 7781-7790		
	R12	JACKSON and HUNTER, "Hordeivirus relationships and genome organization", Annu. Rev. Phytopathol. (1989), 27; 95-121		
	R13	JANDA et al., "High efficiency T7 polymerase synthesis of infectious RNA from cloned brome mosaic virus cDNA and effect of 5' extensions on transcript infectivity", Virology (1987), 158: 259-262		

	Market 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		
Examiner	•	Date	i ·
Signature		Considered	1

Burrier Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231 DO NOT SEND FRES OR COMPLETED FORMS TO THIS ADDRESS SEND TO Assistant Commissioner for Patents. Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is ottoched.

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Tradumark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

3 of

Complete if Known				
Application Number	10/609,207			
Filing Date	June 26, 2003			
First Named Inventor	Lada Rasochova			
Group Art Unit	1638			
Examiner Name	(not yet assigned)			
Attorney Docket Number	WARE-100XCD1			

	NON PATENT LITERATURE DOCUMENTS				
Examiner Inidals*	Cite No. 1	include name of the outhor (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²		
	Ř14	KAIDO et al., "Inhibition of brome mosaic virus (BMV) amplification in protoplasts from transgenic tobacco plants expressing replicable BMV RNAs", J. of Gener. Virology (1995). 76: 2827-2833			
	R15	ISI IlKAWA et al, "Yeast mutations in multiple complementation groups inhibit brome mosaic virus RNA replication and transcription and perturb regulated expression of viral polymerase-like gene" PNAS (1997), 94: 13810-13815			
	R16	LEWANDOWSKI and DAWSON, "Deletion of internal sequences results in tobacco messic virus defective RNAs that accumulate to high levels without interfering with replication of the helper virus", Virology (1998), 251(2): 427-437			
	R17	RASOCHOVA and MILLER, "Satellite RNA of barley yellow dwarf-RPV virus reduces accumulation of RPV helper virus RNA and attenuates RPV symptoms on oats", Molecular Plant-Microbe Interact (1996), 9: 646-650			
	R18	SELLING et al., "Genomic RNA of an insect virus directs synthesis of infectious virions in plants", PNAS (1990), 87: 434-438			
	R19	TIMPE and KUHNE, "In Vitro transcript of a full-length cDNA of a naturally deleted RNA2 of barley mild mosaic virus (BaMMV) replicate in BaMMV-infected plants", J. of General Virology (1995), 76: 2619-2623			
	R20	TÖPFER et al., "A set of plant expression vectors for transcriptional and translational fusions". Nucleic Acids Res. (1987), 15; 5890			
	R21	VAN DER VOSSEN et al., "The 5' terminal sequence of Alfalfa mosaic virus RNA 3 is dispensable for replication and contains a determinant for symptom formation", Virology (1996), 221: 271-280			
	R22	ZHOU and JACKSON, "Analysis of cis-acting elements for replication of barley stripe mesaic virus RNA", Virology (1996), 219: 150-160			
	R23	POLO and DUBENSKY, "DNA vaccines with a kick", Nature Biotech. (1998), 16: 517-518			
	R24	PRICE et al., "Complete replication of an animal virus and maintenance of expression vectors derived from it in Saccharomyces cerevisiae", PNAS (1996), 93: 9465-9470			
	R25	RASOCHOVA et al., "The Satellite RNA of barley yellow dwarf virus-RPV is supported by beet western yellows virus in Dicotyledonous Protoplasts and Plants", Virology (1997), 231: 182-191			
	R26	SACHER of al., "Hybrid brome mosaic virus RNAs express and are packaged in lobacco mosaic virus coat protein in viva", Virology (1988), 167: 15-24			

(Fuerdings	Date
Examinor	Considered
Signature	Considered

^{*}EXAMINER: Initial if reference considered, whether or not cliation is in conformance with MPEP 509. Draw line through citation if not in conformance and not considered include copy of this form with next communication to applicant.

Burden Flour Statement. This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Weshington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO Assistant Commissioner for Patents, Washington, DC 20231.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/03B (10-01)

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Tradomark Office: U.S. DEPARTMENT OF COMMERCE

Under the Papurwerk Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

Substitute for form 1449B/PFO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many shoets as necessary)

of

Sheet

	implete it Known
Application Number	10/609,027
Filing Date	June 26, 2003
First Named Inventor	Lada Rasochova
Group Art Unit	1638
Examiner Name	(not yet assigned)
Attorney Docket Number	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article. (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), dato, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	R27	KASHIWAZAKI et al., "Nucleotide sequence of barley yellow mospic virus RNA1: a close evolutionary relationship with potyviruses", J. of Goneral Virology (1990), 71: 2781-2790	
	Ŕ28	KASHIWAZAKI et al., "Nucleotide sequence of barley yellow mosaic virus RNA2", J. of General Virolgy (1991), 72: 995-999	
	R29	KIKKERT, "The biolistic PDS 1000/He device", Plant Cell Tiss. and Org. Cult. (1993), 33: 221-226	
	R30	MORI et al., "Infectivity of plasmids containing brome mosaic virus cDNA linked to the cauliflower mosaic virus 35S RNA promoter", J. of Gen. Virology (1991), 72: 243-246	
	R31	MORI et al., "Expression of brome mosaic virus-oncoded replicase genes in transgenic tobacco plants", J. of Gen. Virology (1992), 73: 169-172	
	R32	NEELEMAN ot al., "infection of tobacco with alfalfa mosaic virus cDNAs sheds light on the early function of the coat protein", Virology (1993), 196: 883-887	
	R33	PACHA and AHLQUIST, "Use of bromovirus RNA3 hybrids to study template specificity in viral RNA amplification". J. of Virology (1991), 65: 3693-3703	
	f t 34	PETTY and JACKSON, "Mutational analysis of barley stripe mosaic virus RNA beta", Virology (1990), 179: 712-718	
	R35	CROOKE, "Antisense Research and Application", Basic Principles of Antisense Therapeutics (1998), chapter 1	
	R36	BRANCH, "A good antisense molecule is hard to find", <i>TIBS</i> (1998), 45-50	
	R37	PALU et al., "In pursuit of new developments for gene therapy of human diseases", J. of Biotech. (1999), 68: 1-13	4-1
	R38		
	R39		

[Examinor		
	l Date	<u> </u>
l Signature I		
Colgitatore	Consider	ed I

Burdon Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form about be sent to the Chief Information Officer, U.S. Patent and Trademork Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citalion designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached,